Alvine Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing therapeutics for autoimmune/gastrointestinal diseases. Alvine's lead product candidate, ALV003, is a combination protease engineered to digest gluten. It is being developed to treat patients with celiac disease.
Funding Rounds (6) - $138.01MUpdate
Current Team (12)Update
Board Members and Advisors (4)Update
|Mar 16, 2016||SoCal - Tech - ImmunogenX Acquires Alvine Pharmaceuticals|
|Jan 14, 2016||PRNewswire UK All - Celiac Disease Pipeline Review Market Research Report for H2 2015|
|Jul 27, 2015||Business Wire - Research and Markets: Celiac Disease Clinical Trials - Global Review, H1, 2015|
|Jul 13, 2015||Business Wire - Hercules Appoints Dr. Rodney A. Ferguson, Ph.D. to its Board of Directors|
|May 13, 2015||Xconomy - Selecta Takes Nanotech to Gene Therapy, Celiac With New Deals|
|Mar 2, 2015||Fierce Biotech - Amgen hands off an IL-15 drug--strings attached--for upstart effort on celiac disease|
|Dec 22, 2014||Fierce Biotech - ImmusanT banks $12M round for PhII celiac vaccine study|
|Nov 22, 2013||SEC - SEC FORM D/A|
75 Shoreway Rd.
San Carlos, CA 94070